Entrada Therapeutics, Inc.
TRDA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -17.2% | -90.5% | -45% | – |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | -2,276.8% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -2,617.7% | -2,349.5% | -101.4% | -13% |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -2,734.4% | -2,210.4% | -84.4% | 3% |
| EPS Diluted | -1.06 | -1.04 | -0.42 | 0.026 |
| % Growth | -1.9% | -147.6% | -1,697% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |